These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

910 related articles for article (PubMed ID: 36213162)

  • 1. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
    Chen X; Hu G; Xiong L; Xu Q
    Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
    [No Abstract]   [Full Text] [Related]  

  • 2. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
    Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
    Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
    Wang S; Bai H; Fei S; Miao B
    Biochem Genet; 2024 Jun; 62(3):2332-2351. PubMed ID: 37898914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of cuproptosis-related subtypes and development of a prognostic signature in colorectal cancer.
    Huang Y; Yin D; Wu L
    Sci Rep; 2022 Oct; 12(1):17348. PubMed ID: 36253436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
    Liu R; Liu Y; Zhang F; Wei J; Wu L
    Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the cuproptosis-related molecular subtypes and an immunotherapy prognostic model in hepatocellular carcinoma.
    Zhang L; Xu J; Chu X; Zhang H; Yao X; Zhang J; Guo Y
    BMC Bioinformatics; 2022 Nov; 23(1):485. PubMed ID: 36384423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma.
    Li Y; Zeng X
    Front Pharmacol; 2022; 13():1081952. PubMed ID: 36703728
    [No Abstract]   [Full Text] [Related]  

  • 11. Prediction of risk and clinical outcome of cuproptosis in lung squamous carcinoma.
    Zhang Y; Zhou J; Li H; Liu Y; Li J
    BMC Pulm Med; 2023 Jun; 23(1):205. PubMed ID: 37308925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and validation of a novel cuproptosis-related genes signature associated with prognosis, clinical implications and immunotherapy of hepatocellular carcinoma.
    He F; Zeng P; Ma S; Yang X; Liu H; Liu Q; Zhou Y; Zhu H
    Front Pharmacol; 2023; 14():1088993. PubMed ID: 36843949
    [No Abstract]   [Full Text] [Related]  

  • 13. Development and experimental verification of a prognosis model for cuproptosis-related subtypes in HCC.
    Wang Y; Zhang Y; Wang L; Zhang N; Xu W; Zhou J; Zhao Y; Zhu W; Zhang T; Wang L
    Hepatol Int; 2022 Dec; 16(6):1435-1447. PubMed ID: 36065073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC.
    Qin H; Sheng W; Zhang G; Yang Q; Yao S; Yue Y; Zhang P; Zhu Y; Wang Q; Chen Y; Zeng H; Weng J; Yu F; Yang J
    Front Genet; 2023; 14():1094793. PubMed ID: 36891150
    [No Abstract]   [Full Text] [Related]  

  • 15. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.
    Yan C; Niu Y; Ma L; Tian L; Ma J
    J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints.
    Wang X; Chen D; Shi Y; Luo J; Zhang Y; Yuan X; Zhang C; Shu H; Yu W; Tian J
    Front Immunol; 2023; 14():1123231. PubMed ID: 37153542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of cuproptosis-related lncRNAs associated with pancreatic cancer immune microenvironment based on single-cell.
    Sun Y; Yao L; Man C; Gao Z; He R; Fan Y
    Front Immunol; 2023; 14():1220760. PubMed ID: 37822927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.
    Chen Y; Tang L; Huang W; Abisola FH; Zhang Y; Zhang G; Yao L
    Biol Direct; 2023 Feb; 18(1):4. PubMed ID: 36750831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cuproptosis-related signature for clinical prognosis and immunotherapy sensitivity in hepatocellular carcinoma.
    Xu S; Dong K; Gao R; Yang Y; Zhou Y; Luo C; Chen W; Liu SM
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):12249-12263. PubMed ID: 37434092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
    Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
    BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.